• Title/Summary/Keyword: 임상상

Search Result 2,619, Processing Time 0.03 seconds

Design of Clinical Big data-based Verifiability Identification Process through Characterization of Medical Device (의료기기의 특성 분석을 통한 임상 빅데이터 기반 검증 가능성 식별 프로세스 설계)

  • Choi, Yoo-Rim;Park, Ye-Seul;Lee, Jung-Won
    • Annual Conference of KIPS
    • /
    • 2017.11a
    • /
    • pp.753-756
    • /
    • 2017
  • 의료기기는 사람의 생명과 직접적으로 연관되어 있기 때문에 다른 분야의 기기보다 안전성에 대한 검증이 필수적이다. 의료 분야에서는 안전성 검증을 위해 기기의 허가 심사 조건으로서 소수의 피험자를 대상으로 수행되는 임상 시험이 존재한다. 그러나 임상 시험의 경우 의료기기를 직접 사람에게 적용하여 검증을 진행하기 때문에, 인체에 미칠 위해성을 고려하여 전임상 시험을 수행하고 있다. 하지만 전임상 시험은 동물이나 가상의 물체를 대상으로 수행하여 실제 사람에 대한 적용이 아니기 때문에, 임상 시험에 비해 검증에 대한 효력을 갖지 못한다. 따라서 본 연구에서는 피험자의 안전을 보장할 수 있고, 임상 빅데이터에 축적된 실제 환자의 사례를 활용한 신뢰성 있는 검증 방안을 제안하고자 한다. 그러나 현재 식품의약품안전처에서 제공되고 있는 의료기기 품목군은 개발하고자 하는 의료기기의 임상 빅데이터 기반 검증 가능성을 식별하기 어렵다. 그러므로 본 논문에서는 의료기기에 대한 다양한 특성 분석을 통해 임상 빅데이터 기반 검증 가능성을 식별하기 위한 프로세스를 제안한다. 제안하는 프로세스에서는 의료기기의 검증에 요구되는 데이터의 식별을 통해 임상 빅데이터를 이용한 테스트 데이터 수집 및 이를 활용한 신뢰성 높은 검증을 가능케 한다.

Results of Arthroscopic inside to Out Repair of Meniscus Tear (반월상연골 파열에 대한 관절경적 inside to out 봉합술의 결과)

  • Kim, Bo-Hyun;Hwang, In-Sung;Yun, Tae-Bong;Byun, Jae-Yong
    • Journal of the Korean Arthroscopy Society
    • /
    • v.8 no.1
    • /
    • pp.1-8
    • /
    • 2004
  • Purpose: This study examined clinical cure and patients' satisfaction degrees by factors influencing surgical operation results, after arthroscopic inside to out repair as a nonabsorbable suture material, in case of meniscal rupture. Materials and Methods: Materials were 110 cases of 95 patients who could make paces for over 12 months from August 1999 to June 2002. Results were evaluated by clinical cure and subjective satisfaction degrees. This study, concerning those results, analyzed age, term from taking pictures to taking surgical operation, rupture section, rupture length, rupture types, lesion of articular-cartilage, and effects of anterior cruciate ligament operation accompanied. Results: 84 cases(76%) were clinically cured, 98 cases(89%) were subjectively satisfied. In case of accompanying anterior cruciate ligament rupture, and in case that rupture length was below 2 cm, rates of clinical cure and patients subjective satisfaction were significantly high. In case of complex or degenerative rupture, patients satisfaction rates were higher when comparing with clinical cure rates. Conclusion: Various sutures are possible as well as available in case of arthroscopic meniscal inside to out repair using nonabsorbable suture material. It can be concluded that patients age is not absolte consideration in determining the suture of meniscus. In cases of complex rupture, degenerative rupture, ruptures companied by joint-cartilage injuries, considerate consideratin need be paid to choose patients and operations.

  • PDF

신항암제 2-N(2-dimethylaminoethyl) 9-hydroxy ellipticiniam chloride (Datelliptinium)를 이용한 항암제 제 2상 임상시험 모델연구

  • 노재경;노형근;정현철;최진혁
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 1992.05a
    • /
    • pp.58-58
    • /
    • 1992
  • 연구자들은 제 2상 임상시험의 모델을 검토하기 위하여, 비무작위적 제 2상 임상시험을 진행 위선암환자에서 시행하였다. 병리조직학적으로 확인되고, 객관적으로 계측가능 병변이 있는 위선암 환자를 대상으로 하였으며, 위선암의 조직 진단은 위선암의 모든 유형을 포함하였다. 환자는 (Datelliptinium)율 1일 250 mg/$m^2$씩 3일 연속 30분에 걸쳐 정주하고, 매 3주마다 반복하였다. 반응의 완전평가는 초치료전 실시하여, 14-25명의 환자가 포함될 예정으로 시작하여 총 15명의 환자가 포함되었다. 매 환자마다 매 치료 주기전에 평가를 실시하였다. 최소 1주기 (3일 치료)를 끝낸 환자에서도 반응평가가 가능한 것으로 간주하였으며 치료기간은 반응의 정도와 치료에 대한 내약력으로 결정하였고, 만일 치료에 대해 현저한 독성이 발생되지 않는다면, 치료 반응이 계속되는 동안 약물투여를 계속하였다. 국소진행암의 경우 약물의 반응이 현저하고, 환자의 전신상태가 현저히 개선되어 외과적 절제가 가능하면, 관해로 간주하고 외과적 절제를 실시 후 약물은 4회 투여하고 치료 종료 후 추적 관찰할 계획으로 시행하였다.

  • PDF

A Phase I/II Trial of $DCVac/IR^{(R)}$ Dendritic Cell Immunotherapy Combined with Irradiation in Cases of Refractory Colorectal Cancer with Multiple Liver Metastases (기존의 치료에 반응하지 않는 다발성 간전이 대장암 환자에서 방사선조사와 병합한 수지상세포 면역치료의 1, 2상 임상시험)

  • Choi, Young-Min;Lee, Hyung-Sik;Kwon, Hyuk-Chan;Han, Sang-Young;Choi, Jong-Cheol;Chung, Ju-Seop;Kim, Chang-Won;Kim, Dong-Won;Kang, Chi-Duk
    • Radiation Oncology Journal
    • /
    • v.26 no.2
    • /
    • pp.104-112
    • /
    • 2008
  • Purpose: To assess the toxicity and tumor response induced by $DCVac/IR^{(R)}$ dendritic cell(DC) immunotherapy combined with irradiation for refractory colorectal cancer patients with multiple liver metastases. Materials and Methods: Between May 2004 and November 2006, applicants from a pool of refractory colorectal cancer patients with multiple liver metastases were enrolled. The patients were registered after having signed the informed consent form, which had been approved by the Institutional Review Board from the Dong-A University and Busan National University Hospital. DCs were obtained from peripheral blood of each patient, and then cultured in vitro. A total of $6{\times}10^6$ DCs were packed into a vial($DCVac/IR^{(R)}$, 0.5 ml) at the convenience of each patient's schedule. On the day before and on the day of each vaccination, each patient received a 4 Gy radiation dose to the target tumor. On the day of vaccination, the indicated dose of autologous DCs was injected into the irradiated tumor using ultrasound-guided needle injection procedures. A total of four vaccinations were scheduled at three 2-week intervals and one 4 week interval at the Dong-A University and Busan National University Hospital. If the tumor status was deemed to be stable or responding to therapy, an additional vaccination dose or two was approved at 4 week intervals beyond the fourth immunization. A tolerance test for DCs was conducted by injecting a range of doses($3{\times}10^6\;to\;12{\times}10^6$ DCs) after the 3rd injection. Moreover, the maximal tolerable dose was applied to additional patients. Treatment safety was evaluated in all patients who had at least one injection. Treatment feasibility was evaluated by the 10th week by assessing the response of patients having at least 4 injections. For systemic toxicities, the evaluation was performed using the National Cancer Institute Common Toxicity Criteria, whereas adverse effects were recorded using common WHO toxicity criteria. Results: Of the 24 registered patients, 22 received the DCs injections. Moreover, of the 14 patients that applied for the tolerance test, only 11 patients completed it because 3 patients withdrew their testing agreement. A grade 3 or more side effect, which was possibly related to the DC injection, did not occur in additional patients. The $12{\times}10^6$ DC injection was identified as the maximum tolerable dose, and was then injected in an additional 8 patients. Patients tolerated the injection fairly well, with no fatal side effects. In order to assess the feasibility of DC immunotherapy, the response was evaluated in other hepatic lesions outside of the targeted hepatic lesion. The response evaluation was performed in 15 of the 17 patients who received at least 4 injections. Stable and progressive disease was found in 4 and 11 patients, respectively. Conclusion: The DC-based immunotherapy and radiotherapy is theoretically synergistic for the local control and systemic control. The $DCVac/IR^{(R)}$ immunotherapy combined with irradiation was tolerable and safe in the evaluated cases of refractory colorectal cancer with multiple liver metastases. Future work should include well designed a phase II clinical trials.